The importance of the immune system in effective cancer treatment is widely recognized. We show that the new signal-interceptors targeting the JAK-STAT5 pathway may have dangerous side effects that must be taken into account in clinical trials: inhibiting JAK/Stat5 has the potential to promote tumor growth by enhancing NK cell-mediated angiogenesis.
Introduction
Natural Killer (NK) cells are innate lymphocytes that develop from a common lymphoid progenitor in the bone marrow (1) . They represent the first line of defense against infected, stressed and malignant cells. Recent evidence has assigned distinct features and functions to tissue-specific NK cells (2) . NK cells have organ-specific properties such as distinct profiles of receptor expression or cytokine production (3) . Uterine NK cells secrete high levels of VEGF-A and are involved in placental vascularization. The physiological functions of other organ-specific NK-cell subsets are less well understood (4) . Tg mice lack NK cells (8) . It is also important for lymphoid cell development (9) : STAT5 is constitutively active in a plethora of lymphoid malignancies (10) . Recent studies have described somatic Stat5b mutations as active drivers of lymphoid malignancies (11, 12) and considerable efforts are under way to develop STAT5 inhibitors. Such inhibitors will not only target malignant hematopoietic cells but will also have severe consequences for immune functions that depend on the activation of STAT5 by cytokines. A precise understanding of the detailed function of STAT5 in immune cells is required to predict the potential side effects of a STAT5-directed therapy.
We now provide the first evidence that STAT5 is more than a master regulator of NK cell survival, proliferation and cytotoxicity: it also inhibits NK cell-mediated tumor angiogenesis by directly suppressing the transcription of the angiogenic factor VEGF-A. This finding forces us to reconsider the potential consequences of STAT5-directed therapies for NK-cell surveilled tumors.
Results

Overexpression of Bcl-2 rescues survival of STAT5-deficient NK cells
STAT5 regulates the anti-apoptotic genes Bcl-xl, Bcl-2 and Mcl-1 in various cell types (13) (14) (15) (16) (17) .
The lack of expression of these genes would explain the almost complete absence of mature NK (Figure 2A, S2A ).
It is also characterized by reduced mRNA and protein levels of the T-box transcription factor family members T-bet and Eomes ( 
Ncr1-iCre
Tg -vav-bcl-2 NK cells consistently showed a significant reduction in the levels of all effector molecules ( Figure   2E , Figure S3A -C). In line with the reduced STAT5 activation found in non-activated ex vivoderived vav-bcl-2 NK cells we found a decrease in levels of the effector molecules ( Figure 2E and S3A). In contrast, no differences were observed upon activation in interferon-treated cells ( Figure S3B+C ). In vitro cytotoxicity assays confirmed the physiological significance of these observations: NK cells with diminished levels of STAT5 cannot efficiently lyse target cells Figure S3D ).
Loss of STAT5 in NK cells is associated with a tumor-promoting effect in vivo
To study NK cell-mediated tumor surveillance in vivo, we injected 5x10 Figure 4C ). This clearly demonstrates that the NK cells themselves are responsible for the enhanced tumor progression.
NK cells secrete VEGF-A and promote endothelial cell growth
The development of subcutaneous tumors relies on the formation of new blood vessels (28).
CD31 is a marker for angiogenesis and we found significantly more CD31 + cells in tumors 
STAT5 regulates VEGF-A production in mice and human
We have shown that loss or absence of STAT5 is associated with increased levels of VEGF-A.
To investigate how STAT5 interferes with the production of VEGF-A we stimulated ex vivo- 
Methods
Mice
Mice were bred on C57BL/6 background and maintained at the University of Veterinary
Medicine Vienna under pathogen-free conditions. Following mice were studied: Vegf-A (44, 45) were backcrossed with C57BL/6 once and then littermates were crossed for this study.
Cell culture
Splenic NK cells were isolated using the MACS positive selection kit (DX5, Miltenyi) and cultured with 5000U/ml rhIL-2 (Proleukin ® , Roche). NK cell stimulations were performed in the presence of 5.000U/ml rhIL-2 ± 5ng/ml rmIL-12 (R&D), 50ng/ml rmIL-15 (PeproTech), 100U/ml rmIFN-β (Sigma), 5ng/ml rmIL-10 (R&D), 100ng/ml rmIL-21 (Immunotools), 50ng/ml rmIL-23 (R&D), 100ng/ml rmIL-18 (R&D), 50ng/ml rmIL-6 (R&D), 50ng/ml rmIL6Rα (R&D) or 10ng/ml Phorbol-12-myristat-13-acetat (PMA, Sigma) / 250ng/ml ionomycin (Sigma). For in vitro activation of Cre recombinase in NK cells expressing Mx-1Cre, IL-2 expanded NK cells were treated with 1000U/ml rmIFN-β (pbl Assay Science).
For inhibitor studies, splenic mouse or human peripheral blood NK cells were treated for 3 hours with 0.5/1µM Ruxolitinib (Chemietek) or 4 hours with a small-molecule STAT5-Inhibitor (46) and DMSO was used as vehicle control.
RMA and RMA-S cell lines were kindly provided by A.Cerewenka and authenticated by flow cytometry. V-abl + cell lines were generated in the laboratory of Prof.Veronika Sexl. All lines were tested for the presence of mycoplasm by PCR and surface marker expression by flow cytometry every 6 months (last authentication: November 2015).
Spheroid sprouting assays
Murine 
NK cell cytotoxicity
In vitro cytotoxicity assays were performed as previously published (25, 47) .
NK cell depletion
Mice were treated three times by i.p. injection of 100µg PK136 (anti-NK1. 
In vivo tumor challenge
In the B16F10 melanoma model, mice were injected i.v. with 5x10 4 B16F10 cells. After 23 days lungs were analysed. For survival assays, mice were sacrificed at first signs of dyspnea and health detractions.
In the v-abl, RMA and RMA-S tumor model, 5x10 In the A-MuLV model newborn mice were injected with 100 μL of replication-incompetent ecotropic retrovirus encoding for v-abl by s.c. injection as described previously (48) . Mice were checked daily for disease onset.
Drug treatment of mice
Ruxolitinib (Chemietek) was dissolved to make a stock solution in DMSO and further diluted for oral gavage in PBS containing 0.5% methylcellulose (w/v) and 0.1% Tween 80. Mice were treated continuously once a day after tumor cell injection by oral gavage with 95mg/kg Ruxolitinib.
Antibodies and flow cytometry
The following antibodies (clones) were purchased from BD Biosciences: CD3ε(145-2C11), 
Microarray
Data were extracted from ArrayExpress dataset E-GEOD-8059 and E-GEOD-50838 (Affymetrix Human Gene 1.1 ST Arrays). The heatmap was generated using ClustVis software (1). FDR, false discovery rate. 
Statistical analysis
Student's t-test, one-way ANOVA, Tukey's post hoc test and Mantel-Cox log-rank tests (survival curves) tests were performed using GraphPad Prism ® Software version 5.04 and 6.02 (San Diego California USA). For multiple comparison of survival curves, Bonferroni-correction was applied. Statistical analysis is indicated for each experiment specifically (* p < 0.05; ** p < 0.01; *** p < 0.001).
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